Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:162 |
Name | cancer |
Definition | A disease of cellular proliferation that is malignant and primary, characterized by uncontrolled cellular proliferation, local cell invasion and metastasis. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
RET mutant | Sorafenib | cancer | sensitive | detail... |
JAK2 Y931C | Ruxolitinib | cancer | resistant | detail... |
JAK2 V617F JAK2 Y931C | Ruxolitinib | cancer | resistant | detail... |
HRAS wild-type | FTI-277 | cancer | predicted - sensitive | detail... |
JAK2 R683G JAK2 E864K | NVP-BSK805 | cancer | resistant | detail... |
JAK2 R683G JAK2 E864K | NVP-BVB808 | cancer | resistant | detail... |
JAK2 R683G JAK2 G935R | Ruxolitinib | cancer | resistant | detail... |
JAK2 R683G JAK2 G935R | NVP-BSK805 | cancer | resistant | detail... |
JAK2 R683G JAK2 G935R | NVP-BVB808 | cancer | resistant | detail... |
FLT3 I836del | Tandutinib | cancer | sensitive | detail... |
FLT3 I836del | Midostaurin | cancer | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02484053 | Phase I | Rituximab | Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders | Completed | USA | 0 |
NCT03543358 | Phase II | Rovalpituzumab Tesirine | A Long-Term Study of Rovalpituzumab Tesirine | Completed | USA | 0 |
NCT03768063 | FDA approved | Atezolizumab | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) | Recruiting | USA | SVK | ROU | POL | NOR | LVA | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUS | 12 |
NCT03844048 | Phase III | Venetoclax | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | Active, not recruiting | USA | TUR | SWE | POL | NZL | IRL | GRC | GBR | FRA | ESP | DNK | CAN | BEL | AUT | AUS | 8 |
NCT03899155 | FDA approved | Nivolumab | Pan Tumor Nivolumab Rollover Study | Recruiting | USA | TUR | SWE | ROU | POL | NZL | NOR | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
NCT03912831 | Phase I | Cyclophosphamide + Fludarabine KITE-439 | Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers | Terminated | USA | 0 |
NCT03926143 | Phase II | Anetumab ravtansine | A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies | Terminated | USA | POL | ITA | FRA | 0 |
NCT04464226 | Phase III | Darolutamide | Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer | Recruiting | USA | TUR | SWE | SVK | ROU | POL | NLD | LVA | LTU | ITA | ISR | HUN | GBR | FRA | FIN | EST | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 13 |